Oncotarget

Clinical Research Papers:

Primary malignant melanoma of the cervix: Report of 14 cases and review of literature

Guangwen Yuan, Lingying Wu _, Bin Li and Jusheng An

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:73162-73167. https://doi.org/10.18632/oncotarget.17183

Metrics: PDF 1189 views  |   HTML 2598 views  |   ?  


Abstract

Guangwen Yuan1, Lingying Wu1, Bin Li1 and Jusheng An1

1Department of Gynecologic Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, China

Correspondence to:

Lingying Wu, email: [email protected]

Keywords: malignant melanoma, treatment, cervix, prognosis

Received: January 31, 2017    Accepted: March 27, 2017    Published: April 18, 2017

ABSTRACT

Purpose: To investigate the clinical characteristics and prognosis of primary malignant melanoma of the uterine cervix.

Results: The median age of the patients was 61.2 years (range, 42-78 years). The median overall survival of the patients at stage I, II and III were 39.2 months, 47.8 months and 9.0 months (P=0.574) and the 2-year overall survival for each stage were 80.0%, 50.0% and 0.0% respectively. Twelve (85.7%) patients developed recurrence and eleven patients (78.6%) died. Ten patients received surgery and four patients were treated with chemotherapy and/or radiotherapy. Immunotherapy was administrated to two patients after surgery. The mean survival time of patients with surgery and without surgery were 47.9 vs.7.75 months (P=0.047). Patients received radical hysterectomy had longer survival than patients underwent total hysterectomy (66.8 months vs 19.5 months, P=0.016).

Methods: Clinical data from 14 patients with primary malignant melanoma of the cervix between January 1981 and December 2014 were reviewed.

Conclusions: Patients with primary malignant melanoma of the cervix have a poor prognosis. Radical hysterectomy and pelvic lymphnode dissection may offer better prognosis for stage I and II patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17183